The efficacy, safety, and adverse events of azapirones in anxiety disorders: A systematic review and meta-analysis of randomized controlled trials

Azapirones have been proposed as anxiety and mood modulators. We assessed azapirones' viability in anxiety disorders via systematic review and random-effects meta-analysis, inquiring PubMed/MEDLINE/CENTRAL/WHO-ICTRP/WebOfScience/VIP up-to 05/01/2023. We conducted sensitivity, and subgroup analyses assessing heterogeneity, publication bias, risk of bias, and confidence in the evidence within the GRADE framework. Symptom reduction (mean difference/MD), study-defined response (risk ratios/RRs), and acceptability were co-primary outcomes. Adverse events and withdrawal were secondary. Seventy studies were included. In generalized anxiety disorder (GAD), azapirones largely outperformed placebo (MD=-4.91, 95%C.I.[-5.91, -3.90], Hedges'g -1.37 [-1.02, -0.73]), k = 22, n = 2,567; RR=1.64, 95%C.I.[1.45, 1.86], k = 9, n = 1,346). While azapirones overlapped benzodiazepines in symptom reduction (MD=-0.12, 95%C.I.[-0.70, 0.45], k = 34, n = 3,160), they were slightly outperformed in response rate (RR=0.94, 95%C.I.[0.90, 0.99], k = 18, n = 2,423). Azapirones overlapped SRIs (MD=0.09, 95%C.I.[-0.49, 0.67], k = 8, n = 747; RR=0.97, 95%C.I.[0.89, 1.07], k = 7, n = 737). Confidence in estimates was high/moderate vs. placebo, moderate/low vs. benzodiazepine, very-low vs. SRIs. Azapirones failed to outperform the placebo in panic and social anxiety disorders. Azapirones overlapped placebo and SRIs in drop-out rates, while they showed higher treatment discontinuation rates than benzodiazepines (RR=1.33, 95%C.I.[1.16, 1.53], k = 23, n = 2,768). Azapirones caused less sedation/fatigue/drowsiness/weakness/cognitive issues than benzodiazepines, resembling placebo. They caused more nausea and dizziness than placebo, more headache and nausea than benzodiazepines, and less nausea and xerostomia than SRIs. Azapirones proved effective and relatively well-tolerated for GAD. They should be preferred over benzodiazepines, especially in the long-term, considering their lower sedation and addiction potential, representing a potential SRI alternative. Further research is warranted to prove efficacy in panic and social anxiety.

The effects of sustained COVID-19 emergency and restrictions on the mental health of subjects with serious mental illness: A prospective study

Few longitudinal studies have so far investigated the impact of sustained COVID-19 among people with pre-existing psychiatric disorders. We conducted a prospective study involving people with serious mental illness (n = 114) and healthy controls (n = 41) to assess changes in the Perceived Stress Scale, Generalized Anxiety Disorder Scale, Patient Health Questionnaire, and Specific Psychotic Experiences Questionnaire scores 18 months after the COVID-19 pandemic outset. Subjects underwent interviews with a mental health professional in April 2020 and at the end of the local third wave (October 2021). A significant increase in perceived stress was found in healthy controls, especially females. Psychiatric patients showed a significant worsening of anxiety symptoms compared to baseline records (t = -2.3, p = 0.036). Patients who rejected vaccination had significantly higher paranoia scores compared to those willing to get vaccinated (U = 649.5, z = -2.02, p = 0.04). These findings indicate that COVID-19's sustained emergency may cause enduring consequences on mental health, soliciting further investigations.

Relative velocities in bidisperse turbulent suspensions

We investigate the distribution of relative velocities between small heavy particles of different sizes in turbulence by analyzing a statistical model for bidisperse turbulent suspensions, containing particles with two different Stokes numbers. This number, St, is a measure of particle inertia which in turn depends on particle size. When the Stokes numbers are similar, the distribution exhibits power-law tails, just as in the case of equal St. The power-law exponent is a nonanalytic function of the mean Stokes number St[over ¯], so that the exponent cannot be calculated in perturbation theory around the advective limit. When the Stokes-number difference is larger, the power law disappears, but the tails of the distribution still dominate the relative-velocity moments, if St[over ¯] is large enough.

Alexithymia and pain in an outpatient behavioral medicine clinic

Alexithymia is defined as a "lack of words for feelings." This deficiency has been suggested to play a role in the formation and maintenance of somatic symptoms. Prior research has found alexithymia prevalent in "classic" psychosomatic disorders. The present study examines the prevalence of alexithymia and its relationship to patient age, sex, and report of pain. The sample was 208 consecutive outpatients evaluated on a Behavioral Medicine Service and presenting with pain as a primary symptom. Results indicated that the prevalence of alexithymia in this study is consistent with prior research using inpatient pain patients and a similar MMPI alexithymia subscale. Additional analyses of the MMPI clinical and validity scales revealed that alexithymic patients were more defensive and presented themselves in a favorable manner reflecting a "normal" picture of mental health. It is suggested that alexithymia may play a role in chronic pain syndromes. Further research is needed to examine this deficiency and its potential etiological significance in these disorders.